Assessment Of Therapeutic Efficacy Research Articles

A Highly Efficient and User-Friendly Sensitive Skin Model on the Forearm.

Sensitive skin is a worldwide skin problem, and its assessment of therapeutic efficacy traditionally relies on the facial stinging test. However, this test possesses certain limitations due to its restrictive application site, intense pain sensation, and adverse effects on physical appearance. This study aimed to develop and evaluate a highly efficient and user-friendly sensitive skin simulation model, which combines tape stripping and capsaicin testing on the forearm (FA-TS-CAT), as an alternative to the facial stinging test. A randomized, double-blind, placebo-controlled clinical trial was conducted involving 74 subjects. Skin redness (a* value), transepidermal water loss (TEWL), and self-assessment questionnaires were collected at different time points for analysis. Tape stripping 5 times and 10 min application of capsaicin test were identified as the optimal conditions for the FA-TS-CAT model. Consistent stimulation and natural recovery trends of a* value and TEWL were observed on both the FA-TS-CAT and facial capsaicin test (F-CAT) models within 50 min. After the 4-t-butylcyclohexanol complex emulsion was applied, the a* value in the FA-TS-CAT model exhibited a soothing trend similar to the F-CAT model, with a significantly reduced by 3.99-fold and 3.28-fold at T3 and T4 (p < 0.001), compared to the placebo. Notably, the test efficiency of the FA-TS-CAT model was threefold higher than that of the F-CAT model, and subjects showed more willingness to participate in the FA-TS-CAT test (95.95% vs. 4.05%). These results indicated the FA-TS-CAT is a highly efficient and user-friendly model for sensitive skin, providing a reliable and valid method for clinical research in sensitive skin treatment.

Correction: Synergistic effect of “methyl cellulose-dextran” on oral curcumin delivery via casein nanomicelle: fabrication, characterization, and cancer therapeutic efficacy assessment

Correction: Synergistic effect of “methyl cellulose-dextran” on oral curcumin delivery via casein nanomicelle: fabrication, characterization, and cancer therapeutic efficacy assessment

Synergistic effect of “methyl cellulose-dextran” on oral curcumin delivery via casein nanomicelle: fabrication, characterization, and cancer therapeutic efficacy assessment

Synergistic effect of “methyl cellulose-dextran” on oral curcumin delivery via casein nanomicelle: fabrication, characterization, and cancer therapeutic efficacy assessment

Chitosan-ricobendazole complex: Synthesis, characterization and anthelmintic activity

Synthesis, characterization and assessment of therapeutic efficacy of chitosan-ricobendazole complex were carried out for the first time in this work. Study of physico-chemical properties revealed the optimal ratio of chitosan: ricobendazole (30:4). Quantum chemical modeling set the optimal parameters for the formation of the chitosan-ricobendazole molecular system (E = −3765.26 kcal/mol, η = 0.127 eV), which was confirmed by Fourier-transform infrared spectroscopy. Scanning electron microscopy showed spherical particles of chitosan-ricobendazole complex ranging in size from 100 to 200 μm. Study of therapeutic efficiency was conducted on sheep with dicroceliosis. Notably, the therapeutic efficiency of the chitosan-ricobendazole complex (4 mg/kg of ricobendazole) reached 89 %, while the therapeutic efficiency of the commercial preparation ricazole (8 mg/kg of ricobendazole) was 92 %. Biochemical blood test indicated equivalent normalization of hematological parameters in sheep after treatment with ricazole and the chitosan-ricobendazole complex. Histological examination of infected sheep liver revealed that treatment with the chitosan-ricobendazole complex leads to a decrease in the number of helminth eggs with subsequent therapeutic effect on the severity of the disease. This proves the enhanced solubility of ricobendazole at a dosage of 4 mg/kg, active interaction of the components and relatively high bioavailability without increasing the release rate of ricobendazole.

Clinical Case Series on Assessment of Therapeutic Efficacy of Saroglitazar in MASLD Patients

Objective: This prospective case series aimed to evaluate the efficacy of saroglitazar 4 mg in improving clinical parameters in patients with type 2 diabetes mellitus (T2DM) with steatotic liver disease (SLD), focusing on glycemic control, lipid profile, liver enzymes, and transient elastography parameters (CAP and LSM scores). Materials and Methods: Eight T2DM patients having SLD; defined as Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) were enrolled from a single-center, Dr. Dang’s Clinic, Ghaziabad, Uttar Pradesh India. Saroglitazar 4 mg was administered daily, and various clinical parameters were monitored at baseline, 16 weeks, and 32 weeks. Statistical analysis was performed using paired t-tests to assess changes over time. Results: Saroglitazar treatment significantly reduced HbA1c, Triglycerides (TG), Alanine aminotransferase (ALT), transient elastography parameters (CAP and LSM) along with other lipid and glycemic parameters from baseline to weeks 32. These findings underscore potential role of saroglitazar in managing T2DM and associated SLD by improving metabolic parameters and liver health. Conclusion: Saroglitazar showed significant improvements in glycemic control, lipid profile, liver enzymes, liver fat and fibrosis in MASLD patients, indicating its potential as a therapeutic option for managing metabolic abnormalities and liver complications. Further research is needed to validate these findings.

Electrochemical Biosensor Enabling Sensitive Detection of miRNA Biomarkers

Biomarkers are becoming increasingly important for early diagnosis, exploration of responses to medication, and assessment of therapeutic efficacy of various diseases [1]. Increasing evidence shows that miRNAs can be employed as biomarkers for cancer and cardiovascular diseases. In this context, the development of powerful electrochemical diagnostic tools has grown in interest due to their sensitivity, speed, and low cost [1]. Additionally, electrochemical technologies offer a facile means to fabricate well-defined nanostructured surfaces in a controlled environment. The gold (Au)-based surface stands out for its ability to improve charge transfer characteristics, enhancing conductivity. It also serves as a stable substrate for further modification, enabling the detection of target analytes [2]. Here, we utilized an electrochemical platform by using a 3-electrode carbon-based screen-printed electrode (SPE) electrochemically modified with gold and subsequently attached a specific DNA-based redox probe to detect low levels of miRNAs as a biomarker. Our design was applied to detect miRNA-1 (5′-TGG AAT GTA AAG AAG TAT GTA T-3′), demonstrating exceptional sensitivity and a low detection limit (LOD) of 120 fM. We also discuss how the developed platform broadly benefits numerous other miRNA sequences. Device preparation method: A screen-printed electrode (SPE) consisting of a 3 mm diameter carbon working electrode, an Ag reference electrode, and a carbon counter electrode was used as a base for device development. The bare SPE was activated during 10 cycles of cyclic voltammetry (CV) with potentials ranging from -0.5 to +1 V at a scan rate of 20 mVs-1 using PBS as the electrolyte. Before gold electrodeposition, the activated SPE was rinsed with PBS and deionized water. The electrode was submerged in a solution of 115 mM HAuCl4 (in 0.5 M H2SO4) during 10 CV cycles with the same parameters described above. Next, the DNA-probe sequence was attached to the working surface of the Au-decorated screen-printed electrode (Au-SPE). The DNA-probe sequence was modified in advance with C6-S-S-R at the 5′ end (enabling covalent binding onto Au) and methylene blue (MB) at the 3′ end (allowing electron transport at the electrode). Before modification of SPE, the disulfide bond was reduced using tris(2-carboxyethyl)-phosphine hydrochloride) (TCEP) to enable covalently attachment of the HS-DNA-MB probe to the Au-SPE [2]. The attachment of the DNA-probe sequence was achieved by placing 10 µL of the diluted probe onto the working electrode area and allowing for 1 hour of modification at room temperature to take place, as shown in Fig. 1(A). Results & Discussion: The device was evaluated for analytical performance in the presence of increasing target concentrations, as shown in Fig. 1 (A). In the absence of a miRNA-1 target, the stem-loop structure of the DNA probe remains closed, forcing the redox MB-reporter into proximity to the electrode, allowing for efficient electron transport. In the presence of miRNA-1, the target molecule binds to a complementary sequence of the DNA probe, opening the loop. The structure assumes a relatively rigid conformation where MB is farther from the gold surface, reducing the observed signal, Fig. 1 (B). The observed current gradually decreases upon the successive addition of miRNA target molecules for both cathodic, Ipc, and anodic, Iac, peaks. Using the dependence of anodic peak, Iac, the sensor was calibrated as a function of added miRNA-1 concentration in the range between 0 and 4 nM. Using the calibration curve shown in Fig. 1 (C), the detection limit was estimated to be 120 femtoM. The device was further tested for stability and exhibited robust performance over an extended period displaying minimal fluctuations in the recorded current. While we demonstrate the sensitive detection of miRNA-1, the design can be easily adapted for other miRNA sequences [3]. Additionally, it introduces exciting prospects for multiplexing, where multiple miRNA sequences can be easily detected with only minor adjustments to the established design. Fig. 1 (A) Schematics of the device fabrication process and mechanism for the development of Smart Electrochemical Sensors setup; (B) Cyclic Voltammetry (CV) responses during Au electrodeposition (black) in the absence of miRNA-1 target (red) and presence of miRNA-1 target (blue); (C) The device response curve concerning successive addition of miRNA-1 target molecule into the device chamber (different concentrations of target from 0 to ~ 4000 pM), the inset shows CV response used to plot the calibration curve. Acknowledgment: NSF DMR 2204027, US DOE EPSCoR DE-SC0024284

Assessment of therapeutic efficacy of adipose tissue-derived mesenchymal stem cells administration in hyperlipidemia-induced aortic atherosclerosis in adult male albino rats

Atherosclerosis (AS) is a common disease seriously detrimental to human health. AS is a chronic progressive disease related to inflammatory reactions. The present study aimed to characterize and evaluate the effects of adipose tissue stem cells (ADSCs) in high-fat diet-induced atherosclerosis in a rat model. The present study comprises thirty-six rats and they were divided into three groups: the control group, the high-fat diet (HFD) group; which received a high-fat diet, and the high-fat diet + stem cells (HFD+SC) group; which was fed with a high-fat diet along with the administration of intravenous ADSCs. Food was given to the animals for 20 weeks to establish dyslipidemia models. After 20 weeks, animals were sacrificed by cervical dislocation; blood was collected to measure total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL); aortae were collected to detect morphologic changes. Rats of the HFD group showed a significant increase in body weight (B.Wt), altered lipid profile increased expression of inducible nitric oxide synthase (iNOS), and decreased expression of endothelial nitric oxide synthase (eNOS). However, in HFD+SC there was a significant decrease in body weight gain and an improvement in lipid profile. Histopathological and ultrastructural variations observed in the aorta of the HFD group when treated with ADSCs showed preserved normal histological architecture and reduced atherosclerosis compared with the HFD group. This was evidenced by laboratory, histological, immunohistochemical, and morphometric studies. Thus, ADSCs reduced TC, TG, and LDL, reduced the expression of iNOS, and increased the expression of eNOS. The high-fat diet was likely to cause damage to the wall of blood vessels. Systemically transplanted ADSCs could home to the aorta, and further protect the aorta from HFD-induced damage.

Specific Biomarkers in Spinocerebellar Ataxia Type 3: A Systematic Review of Their Potential Uses in Disease Staging and Treatment Assessment

Spinocerebellar ataxia type 3 (SCA3) is the most common type of disease related to poly-glutamine (polyQ) repeats. Its hallmark pathology is related to the abnormal accumulation of ataxin 3 with a longer polyQ tract (polyQ-ATXN3). However, there are other mechanisms related to SCA3 progression that require identifying trait and state biomarkers for a more accurate diagnosis and prognosis. Moreover, the identification of potential pharmacodynamic targets and assessment of therapeutic efficacy necessitates valid biomarker profiles. The aim of this review was to identify potential trait and state biomarkers and their potential value in clinical trials. Our results show that, in SCA3, there are different fluid biomarkers involved in neurodegeneration, oxidative stress, metabolism, miRNA and novel genes. However, neurofilament light chain NfL and polyQ-ATXN3 stand out as the most prevalent in body fluids and SCA3 stages. A heterogeneity analysis of NfL revealed that it may be a valuable state biomarker, particularly when measured in plasma. Nonetheless, since it could be a more beneficial approach to tracking SCA3 progression and clinical trial efficacy, it is more convenient to perform a biomarker profile evaluation than to rely on only one.

Viscosity-activated carbon dots for noninvasive disease diagnosis, therapeutic efficacy assessment and anticancer drug screening

Abnormal levels of intracellular microviscosity have a close relationship with some diseases and pathologies. Therefore, quantitative imaging of viscosity at the cellular and organ levels is beneficial for disease diagnosis, curative effect evaluation, and anticancer drug screening. Herein, we synthesized viscosity-activated orange-red emitting carbon dots (named as LP-CDs) from lignin and p-phenylenediamine using a one-step method, whose fluorescence intensity, lifetime, and quantum yield significantly increase with rising viscosity. Meanwhile, the fluorescence intensity of LP-CDs also has a good linear relationship with the solution viscosity. Taking the advantages of high sensitivity, noninvasiveness, and rapid result output of fluorescence imaging, LP-CDs can visualize the cellular viscosity changes induced by inflammation and hyperglycemia, and image tumor evolution. More importantly, LP-CDs can be used as powerful sensors to screen anticancer drugs in vivo by evaluating therapeutic effects. This work provides a new scheme for constructing robust nanoprobes to achieve the diagnosis and imaging-guided surgery of viscosity related diseases.

Ultrasound Utility in the Management of Morphea: A Comprehensive Review.

Morphea, an autoimmune progressive disorder, can significantly impact patient well-being, yet therapeutic options, though expanding, exhibit limited efficacy. A persistent challenge in disease management revolves around monitoring disease activity and gauging treatment effectiveness. To address this, various clinical assessment tools have been devised, each with its inherent limitations. The realm of imaging in morphea has undergone noteworthy expansion, with ultrasonography (US) emerging as an efficacious and cost-effective avenue for quantifying disease activity and evaluating therapeutic outcomes. However, the evidential support for its application remains equivocal. Our aim was to explore and analyze the existing evidence concerning the utility of ultrasound in the management of morphea. We conducted a comprehensive literature review using PubMed Medline to assess evidence concerning US utility in morphea management. Sixteen total studies were included in our review. Although the studies presented carry their own limitations, cumulative findings indicate the potential of ultrasound, particularly when coupled with Doppler, in facilitating staging, assessing disease activity, and longitudinal assessment of therapeutic efficacy in patients with morphea.

Development of a customizable mouse backbone spectral flow cytometry panel to delineate immune cell populations in normal and tumor tissues.

In vivo studies of cancer biology and assessment of therapeutic efficacy are critical to advancing cancer research and ultimately improving patient outcomes. Murine cancer models have proven to be an invaluable tool in pre-clinical studies. In this context, multi-parameter flow cytometry is a powerful method for elucidating the profile of immune cells within the tumor microenvironment and/or play a role in hematological diseases. However, designing an appropriate multi-parameter panel to comprehensively profile the increasing diversity of immune cells across different murine tissues can be extremely challenging. To address this issue, we designed a panel with 13 fixed markers that define the major immune populations -referred to as the backbone panel- that can be profiled in different tissues but with the option to incorporate up to seven additional fluorochromes, including any marker specific to the study in question. This backbone panel maintains its resolution across different spectral flow cytometers and organs, both hematopoietic and non-hematopoietic, as well as tumors with complex immune microenvironments. Having a robust backbone that can be easily customized with pre-validated drop-in fluorochromes saves time and resources and brings consistency and standardization, making it a versatile solution for immuno-oncology researchers. In addition, the approach presented here can serve as a guide to develop similar types of customizable backbone panels for different research questions requiring high-parameter flow cytometry panels.

Assessment and Risk Prediction of Chronic Kidney Disease and Kidney Fibrosis Using Non-Invasive Biomarkers.

Effective management of chronic kidney disease (CKD), a major health problem worldwide, requires accurate and timely diagnosis, prognosis of progression, assessment of therapeutic efficacy, and, ideally, prediction of drug response. Multiple biomarkers and algorithms for evaluating specific aspects of CKD have been proposed in the literature, many of which are based on a small number of samples. Based on the evidence presented in relevant studies, a comprehensive overview of the different biomarkers applicable for clinical implementation is lacking. This review aims to compile information on the non-invasive diagnostic, prognostic, and predictive biomarkers currently available for the management of CKD and provide guidance on the application of these biomarkers. We specifically focus on biomarkers that have demonstrated added value in prospective studies or those based on prospectively collected samples including at least 100 subjects. Published data demonstrate that several valid non-invasive biomarkers of potential value in the management of CKD are currently available.

Abstract 2836: Assessment of therapeutic antibody efficacy without the interference of murine Fc receptors allows for investigation of human antibody-dependent cellular cytotoxicity mediated by NK cells in the FcResolv™ hIL-15 NOG mouse model

Abstract Targeted antibody therapy is applied to treat various cancer types. In addition to the primary mode of action (MOA), which involves direct binding to the tumor antigen, indirect MOA acting through the constant region (Fc) of the antibody can enhance anti-tumor efficacy. Indirect mechanisms engage the innate immune system, mediated by both the complement system (complement-dependent cytotoxicity (CDC)) and immune cells (antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC)). These indirect mechanisms can complicate the evaluation and accurate assessment of antibody-induced ADCC by human NK cells in current mouse models. In immune-deficient mouse strains (e.g. NOG), false positives and/or negatives may occur due to interactions with murine Fc receptors. These can either result in anti-tumor responses via activation of the murine innate immune system or can interfere with the human-targeted therapy's primary MOA. To study the response to anti-cancer antibodies without the interference of these murine Fc receptor interactions and to investigate ADCC mediated by human NK cells, a novel mouse model deficient in Fc receptors and expressing human IL-15 (FcResolv™ hIL-15 NOG) was employed for testing antibody therapies. Methods: Patient-derived xenograft (PDX) tumor models were transplanted into hIL-15 NOG and FcResolv™ hIL-15 NOG mice. A human head and neck squamous cell carcinoma and a lung adenocarcinoma PDX model were both treated with cetuximab. Treatment with pertuzumab and trastuzumab was applied in a breast ductal carcinoma PDX model. Rituximab treatment was tested in two diffuse large B cell lymphoma PDX models. Based on growth kinetics, the lung cancer PDX model was chosen for further testing of ADCC in the NK cell-humanized FcResolv™ hIL-15 NOG mouse. Results and Conclusion: There was no difference in percent tumor growth inhibition between the FcResolv™ hIL-15 NOG and hIL-15 NOG mice with regards to cetuximab treatment in the lung and head and neck cancer or for trastuzumab treatment of breast ductal carcinoma. However, pertuzumab treatment revealed a false positive efficacy, with the false positive effect more pronounced in hIL-15 NOG mice than in FcResolv™ hIL-15 NOG mice. In one of the lymphoma models, a false negative result was observed. Here, rituximab did not show notable tumor inhibition in the hIL-15 NOG mice but did in the FcResolv™ hIL-15 NOG mice. These results demonstrate that FcResolv™ hIL-15 NOG mice serve as a suitable mouse model for a more accurate assessment of the therapeutic efficacy of anti-tumor antibodies. Additionally, evaluation of human-mediated ADCC of therapeutic antibodies in NK cell-humanized FcResolv™ hIL-15 NOG allows detection of effects specifically mediated by human NK cells. Citation Format: Simone Rhein, Maria Stecklum, Monika Buczek, Janell Richardson, Jens Hoffmann. Assessment of therapeutic antibody efficacy without the interference of murine Fc receptors allows for investigation of human antibody-dependent cellular cytotoxicity mediated by NK cells in the FcResolv™ hIL-15 NOG mouse model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2836.

Abstract 3975: A therapeutic screening platform for assessing antigen-specific T cell-mediated tumor killing in vitro

Abstract Many cancers remain resistant to conventional therapies, consequently there has been an exponential rise in the number of therapeutics harnessing the power of the immune system in an oncology setting, with several remarkable examples of success. High frequencies of infiltrating tumor-specific T cells have been linked to improved patient outcomes, which highlights the importance of uncovering how therapeutics can enhance their function. To explore this functionality in a preclinical setting it is critical to have physiologically relevant models. Here, we demonstrate that common issues, such as low precursor frequencies and restricted HLA-types can be overcome via access to HLA-typed samples and use of expansion platforms which attain high numbers of antigen-specific T cells. Furthermore, we show how these systems enable vaccine immunogenicity screening and assessment of therapeutic efficacy. Healthy blood donations were screened for HLA type and antigen-specific T cells were expanded by either co-culture with peptide-pulsed dendritic cells or polyclonal stimulation following multimer enrichment and FACS sorting. Following expansion, the large number of antigen-specific T cells generated enabled the T cells to be assessed via phenotyping, cytokine secretion, or functional killing assays in a 2D or 3D tumor setting. Tumor targets with either 1) endogenous antigen expression, 2) antigen introduced via lentiviral overexpression or 3) peptide loading of MHC class I were utilized. Validated readouts for measuring antigen-specific killing included flow cytometry and time-lapse imaging (IncuCyte), alongside quantification of antigen-specific IFNɣ responses by ELISpot. These pre-clinical platforms represent a suite of physiologically relevant T cell assays which can be used to perform candidate selection in tumor associated antigen/neoantigen vaccine drug development programs, pharmacological inhibition of checkpoint pathways, or co-stimulatory agonist discovery. In combinatorial approaches with radio- or chemotherapy, the development of novel immunotherapies offers hope to many patients with treatment-resistant cancers. Citation Format: Elsenoor Klaver, Henry Leonard, Elizabeth Lieverse, Oliver Brand, Olivier Reelfs, Christopher Kirkham, Lauren Schewitz-Bowers, Louise Brackenbury. A therapeutic screening platform for assessing antigen-specific T cell-mediated tumor killing in vitro [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3975.

Abstract 951: 3D-PREDICT - An ex vivo precision oncology and clinical trial enrichment platform by Nilogen Oncosystems

Abstract Background: Immuno-oncology (IO) therapy with checkpoint inhibitors has demonstrated a higher response rate, duration of response, and overall survival than chemotherapy. However, predicting which FDA approved IO therapies or pharmaceutical agents, as well as best combinations and delivery sequence, will have optimal patient response remains a significant challenge for personalized medicine. Nilogen Oncosystem’s 3D-PREDICT is a novel ex vivo therapeutic investigative platform that provides a functional model of a patient’s tumor to investigate susceptibility to different therapeutic approaches directly. Derived from core biopsies, the 3D-PREDICT model captures the tumor heterogeneity while preserving the tumor microenvironment by retaining stromal components and cell-cell and cell-extracellular matrix interactions. Here, we employed the 3D-PREDICT platform to compare the efficacy of different immunotherapeutic approaches in various solid tumor indications ex vivo. Methods: Tumoroids from 18-gauge core biopsies from solid tumors were generated using Nilogen Oncosystems’s proprietary mechanical process forgoing any enzymatic digestion or propagation while keeping the spatial contexture of stroma intact. Pooled tumoroids were treated ex vivo for 72 hours with various standard-of-care mono or combo therapy (carboplatin, anti-programmed death-ligand 1 (PD-L1) antibody atezolizumab, anti-CD47 antibody magrolimab, anti-programmed cell death receptor-1 (PD-1) antibody nivolumab, or a combination of magrolimab and atezolizumab). Treatment-mediated immune modulation in tumor microenvironment were analyzed to predict patient response to subjected therapies. Results: Treatment-mediated tumor cell killing activity was evaluated using 3D high throughput confocal imaging and Nilogen Oncosystems’s proprietary algorithm for data analysis. The ex vivo response to checkpoint inhibitors was correlated with retrospective patient clinical information. Tumoroid samples treated with atezolizumab and magrolimab demonstrated enhanced tumor cell killing. Approximately 20% of tumors showed increased CD8 T-cell activation upon ex vivo treatment, correlating with proinflammatory cytokine release in conditioned media. Conclusions: The 3D-PREDICT ex vivo tumoroid platform provides a unique resource to predict patients’ response to treatment, potentially serving as a clinical diagnostic to guide clinical care and stratifying patient procurement into clinical trials. This would allow prospective assessment of therapeutic efficacy ex vivo to match each patient to the most effective and least toxic, to improving outcomes, reducing costs, and assigning therapeutics on a more rational basis. Citation Format: Jared Ehrhart, Seth Currlin, Michelle Ataya, Alliyah Humphrey, Rikhia Chakraborty. 3D-PREDICT - An ex vivo precision oncology and clinical trial enrichment platform by Nilogen Oncosystems [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 951.

Non-Invasive Biomarkers for Diagnosis, Risk Prediction, and Therapy Guidance of Glomerular Kidney Diseases: A Comprehensive Review.

Effective management of glomerular kidney disease, one of the main categories of chronic kidney disease (CKD), requires accurate diagnosis, prognosis of progression, assessment of therapeutic efficacy, and, ideally, prediction of drug response. Multiple biomarkers and algorithms for the assessment of specific aspects of glomerular diseases have been reported in the literature. Though, the vast majority of these have not been implemented in clinical practice or are not available on a global scale due to limited access, missing medical infrastructure, or economical as well as political reasons. The aim of this review is to compile all currently available information on the diagnostic, prognostic, and predictive biomarkers currently available for the management of glomerular diseases, and provide guidance on the application of these biomarkers. As a result of the compiled evidence for the different biomarkers available, we present a decision tree for a non-invasive, biomarker-guided diagnostic path. The data currently available demonstrate that for the large majority of patients with glomerular diseases, valid biomarkers are available. However, despite the obvious disadvantages of kidney biopsy, being invasive and not applicable for monitoring, especially in the context of rare CKD etiologies, kidney biopsy still cannot be replaced by non-invasive strategies.

Exploring the Mechanisms of the Huangqin Qingfei Decoction in Pneumonia Treatment for Lipopolysaccharide-Induced Mouse Model: A Network Pharmacology Analysis and Experimental Validation

Objective: In this study, a network pharmacological approach, and in vivo validation experiments were used to screen the active components of the Huangqin Qingfei decoction (HQFD) for their therapeutic efficacy in pneumonia. Methods: The active ingredients and targets of the HQFD were retrieved from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, while pneumonia-related targets were obtained from GeneCards, Online Mendelian Inheritance in Man, and the Therapeutic Target Database. A protein–protein interaction network was constructed to identify core targets, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses using Metascape. A lipopolysaccharide-induced pneumonia mouse model was established, and verification of the main targets predicted by network pharmacology and therapeutic efficacy assessment was conducted using pathological staining, Western blot, and polymerase chain reaction. Results: We identified 51 active components in the HQFD that primarily affected pneumonia-related targets AKT1, PTGS2, MAPK14, and MMP9. The outcomes of the pathway enrichment analyses conducted by the KEGG and the GO demonstrated that the HQFD regulates genes associated with pathways in cancer, the lipid and atherosclerosis, as well as the AGE-RAGE signaling pathway in diabetic complications. Experiments on animals demonstrated that the AKT1, PTGS2, MAPK14, and MMP9 mRNA expression and p-AKT, p-P38, PTGS2, and MMP9 protein expression in lung tissues were significantly upregulated in the model group when compared to the control group. AKT1, PTGS2, MAPK14, MMP9 mRNA expression, and p-AKT, p-P38, PTGS2, and MMP9 protein expression were all lower in the HQFD groups in contrast to the model group. Conclusions: The effects of HQFD on pneumonia can be attributed to its active ingredients, including beta-sitosterol, wogonin, and quercetin. The mechanism involves multiple targets and pathways, including the PI3K-AKT signaling pathway, MAPK signaling pathway, and NF-kappa B signaling pathway, and modulation of AKT, PTGS2, MAPK14, and MMP9 expression. The HQFD reduces inflammatory damage and pneumonia symptoms via these mechanisms.

HLH as an additional warning sign of inborn errors of immunity beyond familial-HLH in children: a systematic review.

Hemophagocytic Lymphohistiocytosis (HLH) is a rare and life-threatening condition characterized by a severe impairment of the immune homeostasis. While Familial-HLH (FHL) is a known cause, the involvement of other Inborn Errors of Immunity (IEI) in pediatric-HLH remains understudied. This systematic review aimed to assess the clinical features, triggers, laboratory data, treatment, and outcomes of pediatric HLH patients with IEI other than FHL (IEInotFHL), emphasizing the importance of accurate identification and management. A systematic search for studies meeting inclusion criteria was conducted in PubMed, EMBASE, MEDLINE, and Cochrane Central. Quality assessment was performed through JBI criteria. A comprehensive search yielded 108 records meeting inclusion criteria, involving 178 patients. We identified 46 different IEI according to IUIS 2022 Classification. Combined immunodeficiencies, immune dysregulation disorders, and phagocyte defects were the IEI most frequently associated with HLH. In 75% of cases, HLH preceded the IEI diagnosis, often with an unrecognized history of severe infections. Triggers reflected the specific infection susceptibilities within IEI groups. Liver and central nervous system involvement were less common than in FHL cases. Treatment approaches and outcomes varied, with limited long-term follow-up data, limiting the assessment of therapeutic efficacy across IEI groups. A comprehensive evaluation encompassing immunological, infectious, and genetic aspects is essential in pediatric-HLH. Relying solely on FHL or EBV susceptibility disorders tests is insufficient, as diverse other IEI can contribute to HLH. Early recognition of HLH as a potential warning sign can guide timely diagnostic investigations and facilitate tailored therapeutic interventions for improved outcomes. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=371425, PROSPERO, CRD42022371425.

A Smart Responsive Nanotheranostic System for MRI of Tumor Response to Immunotherapy and Enhanced Synergism of Thermo‐Immunotherapy

AbstractThe challenges associated with the assessment of immune checkpoint inhibitor (ICI) therapy and low immunotherapy response observed in patients with poorly immunogenic tumors are addressed. A smart‐responsive nanoprobe MZF@Gd is synthetized based on magnetic resonance tuning (MRET). The nanoprobe is designed to be targeted and cleaved by granzyme B, a marker of cytotoxic T‐cell activation. MZF@Gd consisted of superparamagnetic Mn‐ and Zn‐doped ferrite magnetic nanoparticles (MZF‐MNPs) with a magnetocaloric effect and a paramagnetic contrast agent gadolinium‐diethylenetriamine penta‐acetic acid (Gd‐DTPA). These components are connected by the granzyme B substrate peptides. The activation of the T1WI signal through MRET, following the cleavage of the probe by granzyme B, enabled the accurate evaluation of the ICI therapeutic effect. Subsequently, an active‐targeting magnetothermally responsive nanotheranostic agent FA‐P(MZF@Gd/JQ1) is fabricated. This agent incorporated the MRET probe MZF@Gd, JQ‐1 (an inhibitor of PD‐L1), the thermosensitive copolymer PCL‐b‐P(MEO2MA‐co‐OEGMA), and folic acid on the surface. Nanotheranostic agents killed tumor cells through magnetocaloric effects, stimulated antitumor immunity, and regulated the drug release, thereby achieving a synergistic effect between hyperthermia and immunotherapy. Moreover, MZF@Gd released from the agent sensitively detected the presence of granzyme B at the tumor site, thereby enabling an effective assessment of therapeutic efficacy.

Synthesis of cationic gel-coated hydroxyapatite composites for pH- and thermo-responsive drug delivery in tumor microenvironments

Nanomedicine has gained a significant attention in biomedical science and engineering. It involves design and applications of engineered composites for targeted delivery, diagnostics, imaging, and therapeutic efficacy assessment. Herein, multi-stimuli responsive doxorubicin (DOX) loaded composites were prepared and used for controlled anticancer drug release for antitumor efficacy. In this study, we synthesized the HAp@PP composites by coating Pluronic® P123 and branched polyethylenimine (PP nanogel) on hydroxyapatite (HAp) particles. In-vitro cytotoxicity tests emphasized that HAp@PP composites presented a cell viability of more than 80 % before DOX loading. The fabricated HAp@PP–DOX composites indicated a pH-/thermo-reliant DOX release under tumor microenvironment conditions. Furthermore, the Korsmeyer-Peppas kinetic model yielded the best fit for the release of DOX under the conditions studied. The in-vitro assessment revealed that HAp@PP–DOX had a higher effect that free DOX, with a cell viability less than 25 % and 15 %, respectively, at a DOX concentration of 50 μg/mL. In the context of cancer treatment, the composites have the potential to be more effective than traditional chemotherapy by delivering drugs efficiently.